With Brexit looming and the UK PM Boris Johnson saying last week that we must prepare for ‘no deal’, the pharma industry is on tenterhooks.

Trade-deal details are still murky, and with new permits required for hauliers, the potential for backlogs affecting British ports is very likely. Not an ideal situation for cross-border operators, especially those that distribute refrigerated medicines, or worse, those getting drugs to patients that are in short supply.

Richard Torbett, Chief Executive of The Association of the British Pharmaceutical Industry (ABPI), summed up the mood on both sides of the English channel perfectly when he stated:

“No deal is not in the interest of patients, the pharmaceutical industry, or the economies of the UK and the EU.”

He continued by stressing something we must all hope for, saying “As long as a window of opportunity remains, negotiators must keep talking and agree to a comprehensive deal”.

The clock won’t stop counting, let’s hope that it’s not too late for a radical change of pace and more clearsightedness around the negotiating table.

Whatever the outcome, choosing a partner such as QUINTA-ANALYTICA with decades of global experience is more important now than ever before.

Stay up to date on all the industry news by following us on LinkedIn.

Additional News

  • 18 July 2023

    Challenges of a large-scale study of breast cancer

    Our bioanalytical experts and a high-profile client team up for the development of a new therapy for breast cancer.

  • 29 June 2023

    EU funding for Quinta-Analytica laboratory in Brno (CZ) was succesfully completed.

    After two years, the project to finance new equipment for the Quinta-Analytica laboratory in Brno was successfully completed. The investment from European Regional Development Fund was used in this project.

  • 22 June 2023

    Quinta Analytica Partners with EvidentIQ to Enhance Efficiency of Phase 1 Studies

    EvidentIQ partners with Quinta-Analytica to enhance Phase 1 study efficiency